About Biopharmaceuticals Engineering at UD
Biopharmaceuticals—medicines produced from living cells—have the potential to revolutionize the treatment of cancers, Alzheimer’s Disease, and inflammatory disorders such as rheumatoid arthritis.
The University of Delaware is home to the National Institute for Innovation in Biopharmaceuticals, a national partnership of 120 universities, community colleges, corporations, government agencies and nonprofit organizations aimed at advancing biopharmaceutical manufacturing innovation and workforce development. The institute director is Kelvin Lee, Gore Professor of Chemical & Biomolecular Engineering at the University of Delaware. NIIMBL is one of 14 Manufacturing USA institutes focused on fundamentally advancing U.S. competitiveness in key industries.
Many researchers across the University of Delaware, including faculty members and students in the College of Engineering, are working on key questions around biopharmaceutical innovation, such as how to extend the shelf life of these medicines and much more.
226,636 sq ft
The Ammon-Pinizzotto Biopharmaceutical Innovation Center now under construction on UD’s STAR Campus will house NIIMBL, the Delaware Biotechnology Institute, and UD’s biomedical engineering program, as well as research laboratories in pharmaceutical discovery and molecular and medical sciences.
UD’s Xinqiao Jia secures $4.85 million to advance vocal fold, salivary gland research.
UD undergrad explores biopharmaceutical research.
UD engineers uncover role of surface diffusion in protein transport, which could aid biopharmaceutical processing.
UD partners with Chemours on state-of-the-art research and innovation center
New polymer units created by UD, Penn researchers could enable materials breakthroughs.
Thought leaders explore emerging area of biotherapeutics.